Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: Signals that distinguish the human carcinogen tamoxifen

Toxicology

Volumn 206, Issue 1, 2005, Pages 91-109

  M Pole, Jessica C ^a   Gold, Leslie I ^c   Orton, Terry ^d   Huby, Russell ^d   Carmichael, Paul L ^b  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b UNILEVER RESEARCH   (United Kingdom)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Arrays; Endometrial cancer; Endometrium; Estrogen; Raloxifene; SERM; Tamoxifen

Indexed keywords

DIHYDROFOLATE REDUCTASE; ESTRADIOL; ESTROGEN; MYC PROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CARCINOGENICITY; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; RETINOBLASTOMA; SIGNAL TRANSDUCTION; STROMA CELL; TRANSCRIPTION REGULATION;

CELLS, CULTURED; ENDOMETRIUM; EPITHELIAL CELLS; ESTRADIOL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RALOXIFENE; RNA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STROMAL CELLS; TAMOXIFEN;

EID: 10044264513     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2004.07.005     Document Type: Article

References (66)

1. IARC on tamoxifen, 1996. Environ. Health Perspect. 104, 688.
2. F. Boccardo, P. Bruzzi, A. Rubagotti, G.U. Nicolo, and R. Rosso Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients Oncology 38 1981 281 285
3. T.D. Bui, L. Zhang, M.C. Rees, R. Bicknell, and A.L. Harris Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma Br. J. Cancer 75 1997 1131 1136
4. P.L. Carmichael Mechanisms of action of antiestrogens: relevance to clinical benefits and risks Cancer Invest. 16 1998 604 611
5. P.L. Carmichael, S. Sardar, N. Crooks, P. Neven, I. Van Hoof, A. Ugwumadu, T. Bourne, E. Tomas, P. Hellberg, A.J. Hewer, and D.H. Phillips Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium Carcinogenesis 20 1999 339 342
6. P.L. Carmichael, A.H. Ugwumadu, P. Neven, A.J. Hewer, G.K. Poon, and D.H. Phillips Lack of genotoxicity of tamoxifen in human endometrium Cancer Res. 56 1996 1475 1479
7. P. Carthew, R.E. Edwards, B.M. Nolan, E.A. Martin, R.T. Heydon, I.N. White, and M.J. Tucker Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia Carcinogenesis 21 2000 793 797
8. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation Carcinogenesis 16 1995 1299 1304
9. E. Castro-Rivera, I. Samudio, and S. Safe Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements J. Biol. Chem. 276 2001 30853 30861
10. R. Clarke, M.C. Liu, K.B. Bouker, Z. Gu, R.Y. Lee, Y. Zhu, T.C. Skaar, B. Gomez, K. O'Brien, Y. Wang, and L.A. Hilakivi-Clarke Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 2003 7316 7339
11. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, J.A. Cauley, L. Norton, T. Nickelsen, N.H. Bjarnason, M. Morrow, M.E. Lippman, D. Black, J.E. Glusman, A. Costa, and V.C. Jordan The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 1999 2189 2197
12. R.E. Curtis, J.D. Boice Jr., D.A. Shriner, B.F. Hankey, and J.F. Fraumeni Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer J. Natl. Cancer Inst. 88 1996 832 834
13. J. Elkas, A. Armstrong, J. Pohl, F. Cuttitta, A. Martinez, and K. Gray Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen Obstet. Gynecol. 95 2000 697 703
14. A.R. Fattaey, K. Helin, M.S. Dembski, N. Dyson, E. Harlow, G.A. Vuocolo, M.G. Hanobik, K.M. Haskell, A. Oliff, and D. Defeo-Jones Characterization of the retinoblastoma binding proteins RBP1 and RBP2 Oncogene 8 1993 3149 3156
15. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86 1994 527 537
16. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 1998 1371 1388
17. J. Fujimoto, M. Nishigaki, M. Hori, S. Ichigo, S. Morishita, and T. Tamaya Effects of estradiol and testosterone on the synthesis, expression and degradation of androgen receptor in human uterine endometrial fibroblasts J. Biomed. Sci. 2 1995 160 165
18. M.G. Ghosh, D.A. Thompson, and R.J. Weigel PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer Cancer Res. 60 2000 6367 6375
19. S.R. Goldstein Update on raloxifene to prevent endometrial-breast cancer Eur. J. Cancer 36 Suppl. 4 2000 54 56
20. Y. Gong, L.C. Murphy, and L.J. Murphy Hormonal regulation of proliferation and transforming growth factors gene expression in human endometrial adenocarcinoma xenografts J. Steroid. Biochem. Mol. Biol. 50 1994 13 19
21. P. Greaves, R. Goonetilleke, G. Nunn, J. Topham, and T. Orton Two-year carcinogenicity study of tamoxifen in alderley park wistar-derived rats Cancer Res. 53 1993 3919 3924
22. X.L. Han, and J.G. Liehr Induction of covalent DNA adducts in rodents by tamoxifen Cancer Res. 52 1992 1360 1363
23. D. Hochner-Celnikier, C. Greenfield, Z. Finci-Yeheskel, A. Milwidsky, A. Gutman, D. Goldman-Wohl, S. Yagel, and M. Mayer Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells Mol. Hum. Reprod. 3 1997 1019 1027
24. A.L. Holleran, B. Lindenthal, T.A. Aldaghlas, and J.K. Kelleher Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes Metabolism 47 1998 1504 1513
25. S.M. Ismail The effects of tamoxifen on the uterus Curr. Opin. Obstet. Gynecol. 8 1996 27 31
26. B.S. Katzenellenbogen Estrogen receptors: bioactivities and interactions with cell signaling pathways Biol. Reprod. 54 1996 287 293
27. R.P. Kedar, T.H. Bourne, T.J. Powles, W.P. Collins, S.E. Ashley, D.O. Cosgrove, and S. Campbell Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial Lancet 343 1994 1318 1321
28. P.J. Kushner, D.A. Agard, G.L. Greene, T.S. Scanlan, A.K. Shiau, R.M. Uht, and P. Webb Estrogen receptor pathways to AP-1 J. Steroid. Biochem. Mol. Biol. 74 2000 311 317
29. Y. Kuwashima, M. Kurosumi, Y. Kobayashi, J. Tanuma, K. Suemasu, Y. Higashi, T. Kasamatsu, K. Shiromizu, and K. Kishi Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma Int. J. Gynecol. Pathol. 17 1998 135 139
30. S. Mai, J. Hanley-Hyde, and M. Fluri c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines Oncogene 12 1996 277 288
31. S. Mandlekar, and A.N. Kong Mechanisms of tamoxifen-induced apoptosis Apoptosis 6 2001 469 477
32. E.A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R.C. Garner, D.J. Boocock, E. Mattock, D.W. Pring, K. Dingley, K.W. Turteltaub, L.L. Smith, and I.N. White Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry Cancer Res. 63 2003 8461 8465
33. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen Carcinogenesis 16 1995 1651 1654
34. M.J. Mourits, H. Hollema, E.G. De Vries, K.A. Ten Hoor, P.H. Willemse, and A.G. Van Der Zee Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium Hum. Pathol. 33 2002 341 346
35. G.L. Mutter, J.P. Baak, J.T. Fitzgerald, R. Gray, D. Neuberg, G.A. Kust, R. Gentleman, S.R. Gullans, L.J. Wei, and M. Wilcox Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation Gynecol. Oncol. 83 2001 177 185
36. P. Neven, and I. Vergote Tamoxifen, screening and new oestrogen receptor modulators Best Pract. Res. Clin. Obstet. Gynaecol. 15 2001 365 380
37. P. Neven, and H. Vernaeve Guidelines for monitoring patients taking tamoxifen treatment Drug Saf. 22 2000 1 11
38. J. O'Brien, I. Wilson, T. Orton, and F. Pognan Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity Eur. J. Biochem. 267 2000 5421 5426
39. K. Paech, P. Webb, G.G. Kuiper, S. Nilsson, J. Gustafsson, P.J. Kushner, and T.S. Scanlan Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites Science 277 1997 1508 1510
40. E. Parrott, M. Butterworth, A. Green, I.N. White, and P. Greaves Adenomyosis - a result of disordered stromal differentiation Am. J. Pathol. 159 2001 623 630
41. D.H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis 22 2001 839 849
42. D.H. Phillips, P.L. Carmichael, A. Hewer, K.J. Cole, I.R. Hardcastle, G.K. Poon, A. Keogh, and A.J. Strain Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes Carcinogenesis 17 1996 89 94
43. D.H. Phillips, A. Hewer, I.N. White, and P.B. Farmer Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats Carcinogenesis 15 1994 793 795
44. M.C. Poirier, and L.J. Schild The genotoxicity of tamoxifen: extent and consequences, kona, hawaii, January 23, 2003 Mutagenesis 18 2003 395 399
45. T.J. Powles Efficacy of tamoxifen as treatment of breast cancer Semin. Oncol. 24 1997 S1-48 S41-54
46. F. Rabenoelina, A. Semlali, M.J. Duchesne, G. Freiss, M. Pons, and E. Badia Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade Int. J. Cancer 98 2002 698 706
47. M. Rebhan, V. Chalifa-Caspi, J. Prilusky, and D. Lancet GeneCards: integrating information about genes, proteins and diseases Trends Genet. 13 1997 163
48. A. Resch, E. Biber, M. Seifert, and H. Resch Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer Acta Oncol. 37 1998 661 664
49. R.K. Reynolds, C.A. Owens, and J.A. Roberts Cultured endometrial cancer cells exhibit autocrine growth factor stimulation that is not observed in cultured normal endometrial cells Gynecol. Oncol. 60 1996 380 386
50. J.I. Risinger, G.L. Maxwell, G.V. Chandramouli, A. Jazaeri, O. Aprelikova, T. Patterson, A. Berchuck, and J.C. Barrett Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer Cancer Res. 63 2003 6 11
51. G.M. Rosano, and P.M. Sarrel Ovarian hormones and the cardiovascular system: recent findings Cardiologia 39 1994 275 279
52. L.E. Rutqvist, H. Johansson, T. Signomklao, U. Johansson, T. Fornander, N. Wilking Stockholm Breast Cancer Study Group Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies J. Natl. Cancer Inst. 87 1995 645 651
53. A. Satou, T. Taira, S.M. Iguchi-Ariga, and H. Ariga A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, ac-Myc-binding protein J. Biol. Chem. 276 2001 46562 46567
54. D. Tackels-Horne, M.D. Goodman, A.J. Williams, D.J. Wilson, T. Eskandari, L.M. Vogt, J.F. Boland, U. Scherf, and J.G. Vockley Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling Cancer 92 2001 395 405
55. L.B. Tanko, L. Warming, Y.Z. Bagger, I. Byrjalsen, S. Jensen, and C. Christiansen Serum placental protein 14: a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium Biomarkers 7 2002 257 266
56. S.R. Tannenbaum Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity Semin. Oncol. 24 1997 S18-1 S81-86
57. J.H. van Es, C. Kirkpatrick, M. van de Wetering, M. Molenaar, A. Miles, J. Kuipers, O. Destree, M. Peifer, and H. Clevers Identification of APC2, a homologue of the adenomatous polyposis coli tumour suppressor Curr. Biol. 9 1999 105 108
58. F.E. van Leeuwen, J. Benraadt, J.W. Coebergh, L.A. Kiemeney, C.H. Gimbrere, R. Otter, L.J. Schouten, R.A. Damhuis, M. Bontenbal, and F.W. Diepenhorst Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 1994 448 452
59. M. Vosse, F. Renard, M. Coibion, P. Neven, J.M. Nogaret, and D. Hertens Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring Eur. J. Obstet. Gynecol. Reprod. Biol. 101 2002 58 63
60. P. Webb, G.N. Lopez, R.M. Uht, and P.J. Kushner Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens Mol. Endocrinol. 9 1995 443 456
61. P. Webb, P. Nguyen, C. Valentine, G.N. Lopez, G.R. Kwok, E. McInerney, B.S. Katzenellenbogen, E. Enmark, J.A. Gustafsson, S. Nilsson, and P.J. Kushner The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions Mol. Endocrinol. 13 1999 1672 1685
62. I.N. White The tamoxifen dilemma Carcinogenesis 20 1999 1153 1160
63. I.N. White Anti-oestrogenic drugs and endometrial cancers Toxicol. Lett. 120 2001 21 29
64. I.N. White, F. de Matteis, A. Davies, L.L. Smith, C. Crofton-Sleigh, S. Venitt, A. Hewer, and D.H. Phillips Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells Carcinogenesis 13 1992 2197 2203
65. G.M. Williams, M.J. Iatropoulos, M.V. Djordjevic, and O.P. Kaltenberg The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat Carcinogenesis 14 1993 315 317
66. C.C. Zhang, and D.J. Shapiro Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis J. Biol. Chem. 275 2000 479 486